Diabetic Nephropathy – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Diabetic Nephropathy – Pipeline Review, H2 2019’, provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

– The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Aibios Co Ltd

Algomedix Inc

Allist Shanghai Pharmaceutical Technology Co Ltd

Antisense Therapeutics Ltd

APT Therapeutics Inc

AptaBio Therapeutics Inc

Araim Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

Betagenon AB

Bird Rock Bio Inc

BLR Bio LLC

Boehringer Ingelheim International GmbH

CCRP Therapeutics GmbH

Cellmid Ltd

Certa Therapeutics Pty Ltd

ChemoCentryx Inc

Corbus Pharmaceuticals Inc

CSL Ltd

cStem Regeneration Pharmaceutical Co Ltd

Curacle Co Ltd

Cyclerion Therapeutics Inc

Daiichi Sankyo Co Ltd

Dimerix Bioscience Pty Ltd

Future Medicine Co Ltd

GenKyoTex SA

Gilead Sciences Inc

Glycadia Inc

GNI Group Ltd

Goldfinch Biopharma Inc

Guangzhou Magpie Pharmaceutical Co Ltd

Inspyr Therapeutics Inc

Johnson & Johnson

Liminal BioSciences Inc

MediPost Co Ltd

Merck & Co Inc

Mesoblast Ltd

Mitsubishi Tanabe Pharma Corp

Novartis AG

Novo Nordisk AS

Noxxon Pharma AG

Orbsen Therapeutics Ltd

Paranta Biosciences Ltd

PhytoHealth Corp

ProKidney LLC

Reata Pharmaceuticals Inc

Redx Pharma Plc

Sarfez Pharmaceuticals Inc

Scohia Pharma Inc

Serodus ASA

Sulfateq BV

Teijin Pharma Ltd

Theravance Biopharma Inc

Twoxar Inc

Vidasym Inc

ZyVersa Therapeutics Inc”

Table of Contents

Table of Contents

Introduction

Diabetic Nephropathy Overview

Diabetic Nephropathy Therapeutics Development

Diabetic Nephropathy Therapeutics Assessment

Diabetic Nephropathy Companies Involved in Therapeutics Development

Diabetic Nephropathy Drug Profiles

Diabetic Nephropathy Dormant Projects

Diabetic Nephropathy Discontinued Products

Diabetic Nephropathy Product Development Milestones

Appendix

List of Tables

“List of Tables

Table 1: Number of Products under Development for Diabetic Nephropathy, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Universities/Institutes, H2 2019

Table 6: Products under Development by Companies, H2 2019

Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 10: Products under Development by Universities/Institutes, H2 2019

Table 11: Number of Products by Stage and Target, H2 2019

Table 12: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 13: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 14: Number of Products by Stage and Mechanism of Action, H2 2019

Table 15: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 16: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 17: Number of Products by Stage and Route of Administration, H2 2019

Table 18: Number of Products by Stage and Molecule Type, H2 2019

Table 19: Diabetic Nephropathy – Pipeline by Aibios Co Ltd, H2 2019

Table 20: Diabetic Nephropathy – Pipeline by Algomedix Inc, H2 2019

Table 21: Diabetic Nephropathy – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2019

Table 22: Diabetic Nephropathy – Pipeline by Antisense Therapeutics Ltd, H2 2019

Table 23: Diabetic Nephropathy – Pipeline by APT Therapeutics Inc, H2 2019

Table 24: Diabetic Nephropathy – Pipeline by AptaBio Therapeutics Inc, H2 2019

Table 25: Diabetic Nephropathy – Pipeline by Araim Pharmaceuticals Inc, H2 2019

Table 26: Diabetic Nephropathy – Pipeline by Astellas Pharma Inc, H2 2019

Table 27: Diabetic Nephropathy – Pipeline by AstraZeneca Plc, H2 2019

Table 28: Diabetic Nephropathy – Pipeline by Bayer AG, H2 2019

Table 29: Diabetic Nephropathy – Pipeline by Betagenon AB, H2 2019

Table 30: Diabetic Nephropathy – Pipeline by Bird Rock Bio Inc, H2 2019

Table 31: Diabetic Nephropathy – Pipeline by BLR Bio LLC, H2 2019

Table 32: Diabetic Nephropathy – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 33: Diabetic Nephropathy – Pipeline by CCRP Therapeutics GmbH, H2 2019

Table 34: Diabetic Nephropathy – Pipeline by Cellmid Ltd, H2 2019

Table 35: Diabetic Nephropathy – Pipeline by Certa Therapeutics Pty Ltd, H2 2019

Table 36: Diabetic Nephropathy – Pipeline by ChemoCentryx Inc, H2 2019

Table 37: Diabetic Nephropathy – Pipeline by Corbus Pharmaceuticals Inc, H2 2019

Table 38: Diabetic Nephropathy – Pipeline by CSL Ltd, H2 2019

Table 39: Diabetic Nephropathy – Pipeline by cStem Regeneration Pharmaceutical Co Ltd, H2 2019

Table 40: Diabetic Nephropathy – Pipeline by Curacle Co Ltd, H2 2019

Table 41: Diabetic Nephropathy – Pipeline by Cyclerion Therapeutics Inc, H2 2019

Table 42: Diabetic Nephropathy – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Table 43: Diabetic Nephropathy – Pipeline by Dimerix Bioscience Pty Ltd, H2 2019

Table 44: Diabetic Nephropathy – Pipeline by Future Medicine Co Ltd, H2 2019

Table 45: Diabetic Nephropathy – Pipeline by GenKyoTex SA, H2 2019

Table 46: Diabetic Nephropathy – Pipeline by Gilead Sciences Inc, H2 2019

Table 47: Diabetic Nephropathy – Pipeline by Glycadia Inc, H2 2019

Table 48: Diabetic Nephropathy – Pipeline by GNI Group Ltd, H2 2019

Table 49: Diabetic Nephropathy – Pipeline by Goldfinch Biopharma Inc, H2 2019

Table 50: Diabetic Nephropathy – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019

Table 51: Diabetic Nephropathy – Pipeline by Inspyr Therapeutics Inc, H2 2019

Table 52: Diabetic Nephropathy – Pipeline by Johnson & Johnson, H2 2019

Table 53: Diabetic Nephropathy – Pipeline by Liminal BioSciences Inc, H2 2019

Table 54: Diabetic Nephropathy – Pipeline by MediPost Co Ltd, H2 2019

Table 55: Diabetic Nephropathy – Pipeline by Merck & Co Inc, H2 2019

Table 56: Diabetic Nephropathy – Pipeline by Mesoblast Ltd, H2 2019

Table 57: Diabetic Nephropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019

Table 58: Diabetic Nephropathy – Pipeline by Novartis AG, H2 2019

Table 59: Diabetic Nephropathy – Pipeline by Novo Nordisk AS, H2 2019

Table 60: Diabetic Nephropathy – Pipeline by Noxxon Pharma AG, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Diabetic Nephropathy, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared